Clinical implications of inflammatory bowel disease genetics on phenotype

Inflammatory Bowel Diseases

Volumn 11, Issue 1, 2005, Pages 56-61

  Fraser Cummings, J R ^a   Jewell, Derek P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Crohn's disease; Genotype; Inflammatory bowel disease; Phenotype; Ulcerative colitis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID; FUNGUS ANTIBODY; HLA ANTIGEN; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; INTERLEUKIN 6; MULTIDRUG RESISTANCE PROTEIN 1; NEUTROPHIL CYTOPLASMIC ANTIBODY; SALAZOSULFAPYRIDINE;

CLINICAL FEATURE; CLINICAL GENETICS; CROHN DISEASE; DATA ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; ENTERITIS; ENVIRONMENTAL FACTOR; EVIDENCE BASED MEDICINE; GENOTYPE PHENOTYPE CORRELATION; HEREDITY; HISTOPATHOLOGY; HUMAN; INTESTINE ENDOSCOPY; INTESTINE RADIOGRAPHY; MEDICAL RESEARCH; PATIENT CARE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REVIEW; SEROLOGY; TREATMENT OUTCOME; TREATMENT PLANNING; ULCERATIVE COLITIS; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; PATHOLOGY; PATIENT CARE PLANNING; PROGNOSIS;

GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; PATIENT CARE PLANNING; PHENOTYPE; PROGNOSIS;

EID: 14844337460     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200501000-00008     Document Type: Review

References (68)

1. Tysk C, Lindberg E, Jarnerot G, et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut. 1988;29:990-996.
2. Halfvarson J, Bodin L, Tysk C, et al. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology. 2003; 124:1767-1773.
3. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
4. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
5. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411:599-603.
6. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn's disease. Nat Genet. 2004;36:471-475.
7. Bridger S, Lee JC, Bjarnason I, et al. In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non-smokers develop ulcerative colitis. Gut. 2002; 51:21-25.
8. Steinhart AH, Girgrah N, McLeod RS. Reliability of a Crohn's disease clinical classification scheme based on disease behaviour. Inflamm Bowel Dis. 1998;4:228-234.
9. Silverberg MS, Daly MJ, Moskovitz DN, et al. Diagnostic misclassification reduces the ability to detect linkage in inflammatory bowel disease genetic studies. Gut. 2001;49:773-776.
10. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777-782.
11. Smith BRK, Arnott IDR, Drummond HE, et al. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behaviour in Crohn's disease. Inflamm Bowel Dis. 2004;10:521-528.
12. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behaviour of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250.
13. Nadeau JH. Modifier genes in mice and humans. Nat Rev Genet. 2001;2: 165-174.
14. Moum B, Ekbom A, Vatn MH, et al. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol. 1999;94:1564-1569.
15. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424.
16. El-Omar EM, Carrington M, Chow WH, et al. The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer. Nature. 2001;412: 99.
17. Hooper LV, Wong MH, Thelin T, et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science. 2001;291:881-884.
18. Arnott ID, Nimmo ER, Drummond HE, et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun. 2004;5:417-425.
19. Inoue N, Tamura K, Kinouchi Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology. 2002;123: 86-91.
20. Yamazaki K, Takazoe M, Tanaka T, et al. Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease. J Hum Genet. 2002;47:469-472.
21. Leong RW, Armuzzi A, Ahmad T, et al. NOD2/CARD15 gene polymerphisms and Crohn's disease in the Chinese population. Aliment Pharmacol Ther. 2003;17:1465-1470.
22. Croucher PJ, Mascheretti S, Hampe J, et al. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet. 2003;11:6-16.
23. Bonen DK, Nicolae DL, Moran A, et al. Racial differences in NOD2 variation: characterization of NOD2 in African-Americans with Crohn's disease. Gastroenterology. 2002; 122:A29.
24. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002;123:679-688.
25. Sugimura K, Taylor KD, Lin YC, et al. A novel NOD2/CARD15 haplotype conferring risk for Crohn's disease in Ashkenazi Jews. Am J Hum Genet. 2003;72:509-518.
26. Zhou Z, Lin XY, Akolkar PN, et al. Variation at NOD2/CARD15 in familial and sporadic cases of Crohn's disease in the Ashkenazi Jewish population. Am J Gastroenterol. 2002; 97:3095-3101.
27. van Heel DA, Dechairo BM, Dawson G, et al. The IBD6 Crohn's disease locus demonstrates complex interactions with CARD15 and IBD5 disease-associated variants. Hum Mol Genet. 2003; 12:2569-2575.
28. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2 mediated T helper type 1 responses. Nat Immunol. 2004;5:800-808.
29. Rioux JD, Silverberg MS, Daly MJ, et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet. 2000;66:1863-1870.
30. Armuzzi A, Ahmad T, Ling KL, et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut. 2003;52:1133-1139.
31. Negoro K, McGovern DP, Kinouchi Y, et al. Analysis of the IBD5 locus and potential gene-gene interactions in Crohn's disease. Gut. 2003;52: 541-546.
32. Aithal GP, Day CP, Leathart J, et al. Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population. Genes Immun. 2001;2: 44-47.
33. Klein W, Tromm A, Griga T, et al. The polymorphism at position -174 of the IL-6 gene is not associated with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2001;13:45-47.
34. Klein W, Tromm A, Griga T, et al. A polymorphism in the CD14 gene is associated with Crohn's disease. Scand J Gastroenterol 2002;37:189-191.
35. Miner P, Wedel M, Bane B, et al. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther. 2004;19: 281-286.
36. Braun C, Zahn R, Martin K, et al. Polymorphisms of the ICAM-1 gene are associated with inflammatory bowel disease, regardless of the p-ANCA status. Clin Immunol. 2001;101:357-360.
37. Matsuzawa J, Sugimura K, Matsuda Y, et al. Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in a Japanese population. Gut. 2003;52:75-78.
38. Low JH, Williams FA, Yang X, et al. Inflammatory bowel disease is linked to 19p13 and associated with ICAM-1. Inflamm Bowel Dis. 2004; 10:173-181.
39. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 2004;36:476-480.
40. Colombel J-F, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
41. Ahmad T, Tamboli CP, Jewell D, et al. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology. 2004;126: 1533-1549.
42. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002;122: 854-866.
43. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845-857.
44. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002;122:867-874.
45. Brant SR, Picco MF, Achkar JP, et al. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis. 2003;9:281-289.
46. Rioux JD, Daly MJ, Silverberg MS, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn's disease. Nat Genet. 2001;29:223-228.
47. Giallourakis C, Stoll M, Miller K, et al. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn's disease and identification of a novel association with ulcerative colitis. Am J Hum Genet. 2003;73:205-211.
48. McGovern DP, Van Heel DA, Negoro K, et al. Further evidence of IBD5/CARD15 (NOD2) epistasis in the susceptibility to ulcerative colitis. Am J Hum Genet. 2003;73:1465-1466.
49. Mirza MM, Fisher SA, King K, et al. Genetic evidence for interaction of the 5q31 cytokine locus and the CARD15 gene in Crohn's disease. Am J Hum Genet. 2003;72:1018-1022.
50. Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic markers may predict disease behaviour in patients with ulcerative colitis. Gastroenterology. 1997;112:1845-1853.
51. Bouma G, Crusius JB, Garcia-Gonzalez MA, et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol. 1999;115:294-300.
52. Newman B, Silverberg MS, Gu X, et al. CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's disease. Am J Gastroenterol. 2004;99:306-315.
53. Bouma G, Poen AC, Garcia-Gonzalez MA, et al. HLA-DRB1*03, but not the TNFA -308 promoter gene polymorphism, confers protection against fistulising Crohn's disease. Immunogenetics. 1998;47:451-455.
54. Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology. 2000;118:274-278.
55. Orchard TR, Chua CN, Ahmad T, et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology. 2002;123:714-718.
56. McGovern DPB, Ahmad T, van Heel D, et al. A genetic panel strongly predicts the need for colectomy in ulcerative colitis. Gastroenterology. 2004;126:A68.
57. Dilger K, Schwab S, Fromm MF. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis. 2004;10:573-578.
58. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 2003;124:26-33.
59. Brant SR, Panhuysen CI, Nicolae D, et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet. 2003; 73:1282-1292.
60. Farrell R, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology. 2000;118:279-288.
61. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut. 2003;52:759-766.
62. Forcione DG, Rosen MJ, Kisiel JB, et al. Anti- Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004;53:1117-1122.
63. Fleshner PR, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut. 2001; 49:671-677.
64. Landewe RB. The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum. 2003; 48:1-5.
65. Landewe RB, van der Heijde DM. Early rheumatoid arthritis: toward tailor-made therapy. Curr Rheumatol Rep. 2003;5:287-293.
66. Lard LR, Boers M, Verhoeven A, et al. Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum. 2002;46:899-905.
67. Vermeire S. NOD2/CARD15: relevance in clinical practice. Best Pract Res Clin Gastroenterol. 2004;18:569-575.
68. Ahmad T, Marshall S, Jewell D. Genotype-based phenotyping heralds a new taxonomy for inflammatory bowel disease. Curr Opin Gastroenterol. 2003;19:327-335.